John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 8,900 shares at $170.83 ($1.5M) on 2021-07-16, disclosed to the SEC on 2021-07-20.
Open-market sale of $1.5M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $168.57 | 500 | $84K | 5.6% |
| 2 | $169.75 | 1,710 | $290K | 19.1% |
| 3 | $169.75 | 1,710 | $290K | 19.1% |
| 4 | $170.83 | 2,190 | $374K | 24.7% |
| 5 | $170.83 | 2,190 | $374K | 24.7% |
| 6 | $171.44 | 600 |
| $103K |
| 6.8% |
| Total | $170.33 avg | 8,900 | $1.5M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |